172 249

Cited 0 times in

Risk of Dementia in Older Patients with Type 2 Diabetes on Dipeptidyl-Peptidase IV Inhibitors Versus Sulfonylureas: A Real-World Population-Based Cohort Study

DC Field Value Language
dc.contributor.authorKim, YG-
dc.contributor.authorJeon, JY-
dc.contributor.authorKim, HJ-
dc.contributor.authorKim, DJ-
dc.contributor.authorLee, KW-
dc.contributor.authorMoon, SY-
dc.contributor.authorHan, SJ-
dc.date.accessioned2020-10-21T07:20:17Z-
dc.date.available2020-10-21T07:20:17Z-
dc.date.issued2019-
dc.identifier.urihttp://repository.ajou.ac.kr/handle/201003/18728-
dc.description.abstractBACKGROUND: Type 2 diabetes is related to an increased risk of dementia. Preclinical studies of dipeptidyl peptidase-IV inhibitors (DPP-4i) for dementia have yielded promising results. Therefore, we investigated the risk of dementia in elderly patients with type 2 diabetes on DPP-4is and sulfonylureas (SU).
METHODS: Using a claims database called the Korean National Health Insurance Service Senior cohort, new users of DPP-4is and SUs were matched by 1:1 propensity score matching using 49 confounding variables (7552 new DPP-4is users and 7552 new SU users were matched by 1:1 propensity score matching: average age 75.4: mean follow-up period: 1361.9 days). Survival analysis was performed to estimate the risk of dementia.
RESULTS: The risk of all-cause dementia was lower in the DPP-4i group compared to the SU group (hazard ratio (HR) 0.66: 95% confidence interval (CI) 0.56(-)0.78: p < 0.001). Particularly, DPP-4i use showed a significantly lower risk of Alzheimer's disease (HR 0.64: 95% CI 0.52(-)0.79: p < 0.001) and a lower risk, albeit non-significant, of vascular dementia compared to SU use (HR 0.66: 95% CI 0.38(-)1.14: p = 0.139).
CONCLUSION: Our findings suggest that DPP-4i use decreases the risk of dementia compared to SU use in elderly patients with type 2 diabetes in a real-world clinical setting.
-
dc.language.isoen-
dc.titleRisk of Dementia in Older Patients with Type 2 Diabetes on Dipeptidyl-Peptidase IV Inhibitors Versus Sulfonylureas: A Real-World Population-Based Cohort Study-
dc.typeArticle-
dc.identifier.pmid30597861-
dc.identifier.urlhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6352270/-
dc.subject.keywordAlzheimer’s disease-
dc.subject.keyworddementia-
dc.subject.keyworddiabetes mellitus-
dc.subject.keyworddipeptidyl-peptidase IV inhibitors-
dc.subject.keywordtype 2-
dc.subject.keywordvascular-
dc.contributor.affiliatedAuthor전, 자영-
dc.contributor.affiliatedAuthor김, 혜진-
dc.contributor.affiliatedAuthor김, 대중-
dc.contributor.affiliatedAuthor이, 관우-
dc.contributor.affiliatedAuthor문, 소영-
dc.contributor.affiliatedAuthor한, 승진-
dc.type.localJournal Papers-
dc.identifier.doi10.3390/jcm8010028-
dc.citation.titleJournal of clinical medicine-
dc.citation.volume8-
dc.citation.number1-
dc.citation.date2019-
dc.citation.startPage28-
dc.citation.endPage28-
dc.identifier.bibliographicCitationJournal of clinical medicine, 8(1). : 28-28, 2019-
dc.identifier.eissn2077-0383-
dc.relation.journalidJ020770383-
Appears in Collections:
Journal Papers > School of Medicine / Graduate School of Medicine > Endocrinology & Metabolism
Journal Papers > School of Medicine / Graduate School of Medicine > Neurology
Files in This Item:
30597861.pdfDownload

qrcode

해당 아이템을 이메일로 공유하기 원하시면 인증을 거치시기 바랍니다.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse